Disulfiram / CSCs Cancer Research Results

Main Actions:
-Potent copper-dependent pro-oxidant
-Targets ALDH⁺ cancer stem cells
-Strong clinical repurposing interest

Key pathways
-Cu-mediated redox cycling
-Proteasome inhibition
-Mitochondrial ROS

Chemo relevance
-Often synergistic
-Highly mechanism-dependent

Disulfiram — a synthetic thiuram disulfide small molecule clinically used as an alcohol-deterrent drug. It is formally classified as an aldehyde dehydrogenase inhibitor and drug-repurposing candidate; standard abbreviations are DSF and, historically, Antabuse. Following administration, DSF is rapidly converted to diethyldithiocarbamate and other metabolites. In cancer models, the most compelling activity is generally attributed not to direct ALDH inhibition by parent DSF, but to formation of the copper-containing metabolite bis(diethyldithiocarbamate)-copper, commonly termed CuET or DSF–Cu. CuET preferentially accumulates under some tumour-associated conditions and disrupts protein homeostasis by targeting the NPL4 adaptor of the p97/VCP segregase.

Primary mechanisms (ranked):

1. Copper-dependent CuET formation and aggregation of NPL4, disabling the p97/VCP segregase and producing severe proteotoxic stress.
2. Disruption of ubiquitin-dependent protein processing, replication-fork maintenance and DNA-damage responses, including impaired ATR-pathway signaling.
3. Oxidative and mitochondrial stress, including increased ROS, loss of mitochondrial membrane potential and activation of apoptotic or non-apoptotic cell death.
4. Suppression of tumour-cell survival programs, including NF-κB, AKT and context-dependent MAPK signaling.
5. Ferroptosis sensitization through ROS, glutathione depletion and lipid peroxidation; NRF2 and HO-1 can provide adaptive resistance rather than serving as a uniformly inhibited primary target.
6. Inhibition of cancer stem-like phenotypes and ALDH activity, although ALDH inhibition is not considered the principal explanation for CuET-mediated anticancer cytotoxicity.
7. Chemosensitization and radiosensitization through proteotoxic stress, defective DNA-damage repair and increased oxidative injury.

Bioavailability / PK relevance: Oral DSF is absorbed but undergoes extensive and variable first-pass metabolism and rapid conversion into diethyldithiocarbamate, methylated metabolites, carbon disulfide and downstream sulfur-containing products. Parent DSF is therefore an unreliable systemic exposure marker. Anticancer translation depends on production, distribution and tumour delivery of CuET or related copper complexes; oral copper supplementation does not guarantee therapeutically adequate intratumoural CuET and introduces additional toxicity and pharmacologic variability.

In-vitro vs systemic exposure relevance: Many experiments add micromolar DSF and excess copper directly to culture medium, allowing rapid extracellular CuET formation. These conditions may substantially exceed or poorly reproduce the concentrations, copper speciation, protein binding and metabolite distribution achieved after conventional oral DSF. Results obtained with DSF–Cu or preformed CuET should not be interpreted as equivalent to exposure from standard DSF dosing.

Clinical evidence status: Extensive preclinical evidence and several small phase I or phase II oncology studies are available, including combinations with chemotherapy, radiotherapy or copper. A small randomized NSCLC study reported a possible survival signal, but subsequent glioblastoma trials were negative or insufficiently active, and the overall clinical evidence remains inconsistent. Disulfiram is not approved by FDA, Health Canada or EMA as an anticancer therapy. Any oncology use, particularly with copper supplementation, remains investigational and should occur within a clinical trial.

Major safety constraints: Alcohol exposure can produce a potentially severe disulfiram–ethanol reaction and must be avoided during treatment and for up to 14 days after discontinuation. Important risks include hepatitis or liver failure, peripheral neuropathy, optic neuritis, psychiatric reactions and clinically significant interactions with metronidazole, warfarin, phenytoin and several CYP-metabolized drugs. Baseline and follow-up hepatic monitoring are important. Added copper may increase gastrointestinal, hepatic and neurologic toxicity and should not be regarded as a benign supplement in an oncology regimen.

Disulfiram Mechanistic Profile

P: 0–30 min    R: 30 min–3 hr    G: >3 hr